西罗莫司对高脂饮食诱导的NAFLD大鼠外周血Treg/Th17细胞的影响

doi:10.3969/j.issn.1672-5069.2021.01.004

摘要/Abstract

摘要： 目的研究西罗莫司对高脂饮食诱导的非酒精性脂肪性肝病(NAFLD)大鼠外周血Treg/Th17细胞的影响。方法随机将60只SD大鼠分为西罗莫司干预组、模型组和对照组,每组20只。采用高脂饮食喂养12周建立NAFLD模型,在造模成功后,在其中20只动物,给予西罗莫司干预2周。采用ELISA法检测血清白介素-10(IL-10)、IL-17和肿瘤坏死因子-α(TNF-α)水平,使用全自动生化分析仪检测血生化指标,使用FACSVia型流式细胞仪检测外周血Treg和Th17细胞百分比。结果干预后,西罗莫司干预组血清AST和ALT水平分别为(134.9±15.3)U/L和(109.4±18.2)U/L,显著低于模型组【(151.1±28.9)U/L和(128.9±17.7)U/L,P<0.05】;血清TG、TC和LDL-C水平分别为(0.9±0.3)mmol/L、(2.6±0.8)mmol/L和(3.3±1.2)mmol/L,显著低于模型组【(1.1±0.5)mmol/L、(3.6±1.3)mmol/L和(5.4±1.8)mmol/L,P＜0.05】,而血清HDL-C水平为(1.3±0.5)mmol/L,显著高于模型组【(0.7±0.4) mmol/L,P＜0.05】;血清IL-10水平为(68.9±26.6)pg/ml,显著高于模型组【(37.8±17.2)pg/ml,P＜0.05],而血清IL-17和TNF-α水平分别为(13.2±3.3)pg/ml和(0.7±0.2)ng/ml,显著低于模型组【(22.6±4.0)pg/ml和(1.2±0.4)ng/ml,P＜0.05】;西罗莫司干预组外周血Treg细胞百分比为(4.5±0.7)%,Th17细胞百分比为(1.7±0.6)%,Treg/Th17比值为(2.6±0.7),与模型组比,差异显著【(3.8±0.9)%、(2.8±1.1)%和(1.5±0.7),P＜0.05]。结论应用西罗莫司干预高脂饮食诱导的NAFLD大鼠能减轻炎症反应,纠正外周血Treg/Th17细胞比值失衡状态,可能有助于阻止NAFLD进展,值得进一步研究。

关键词: 非酒精性脂肪性肝病, 高脂饮食, 西罗莫司, Treg/Th17细胞比值, 大鼠

Abstract: Objective The aim of this study was to investigate the effect of sirolimus on peripheral blood Treg/Th17 cell ratio in high fat diet-inducednon-alcoholic fatty liver disease (NAFLD) in rats. Methods 60 SD rats were randomly divided into sirolimus intervention group, model group and control group with 20 rats in each group. The NAFLD model was established by high fat diet feeding for 12 weeks and when the model was successfully built up, 20 rats were fed with sirolimus for two weeks.Serum aspartate aminotransferase(AST),alanine aminotransferase (ALT)], blood triglyceride(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C)], serum interleukin-10(IL-10), IL-17,tumor necrosis factor-α(TNF-α)] and peripheral blood regulatory T lymphocyte (Treg)/T help cell 17(Th17) were detected. Results At the end of the experiment, serum AST and ALT levels insirolimus-intervened group were (134.9±15.3)U/L and (109.4±18.2)U/L, both significantly lower than 【(151.1±28.9)U/L and (128.9±17.7)U/L, respectively,P<0.05】 in model group; blool TG, TC and LDL-C levels were (0.9±0.3)mmol/L, (2.6±0.8)mmol/L and (3.3±1.2)mmol/L, significantly lower than 【(1.1±0.5)mmol/L, (3.6±1.3)mmol/L and (5.4±1.8)mmol/L, respectively, P＜0.05】 in the model, while blood HDL-C level was (1.3±0.5)mmol/L, much higher than 【(0.7±0.4) mmol/L, P＜0.05】 in the model; serum IL-10 level was (68.9±26.6)pg/ml, much higher than 【(37.8±17.2)pg/ml, P＜0.05], while serum IL-17 and TNF-α levels were (13.2±3.3)pg/ml and (0.7±0.2)ng/ml, significantly lower than 【(22.6±4.0)pg/ml and(1.2±0.4)ng/ml, P＜0.05】 in the model; the percentage of Treg cells was (4.5±0.7)%, the percentage of Th17 cells was (1.7±0.6)% and the ratio of Treg/Th17 cells was (2.6±0.7), significantly different compared to 【(3.8±0.9)%, (2.8±1.1)% and(1.5±0.7), respectively, P＜0.05] in the model.Conclusion The administration of sirolimus could inhibit inflammatory response and correct Treg / Th17 cell imbalance in rats with high fat diet-induced NAFLD, which mightalleviates hepatic steatosis.

Key words: Non-alcoholic fatty liver disease, Sirolimus, High fat diet, Treg / Th17 cells, Rats

荣爱梅, 张超, 吴慧丽. 西罗莫司对高脂饮食诱导的NAFLD大鼠外周血Treg/Th17细胞的影响[J]. 实用肝脏病杂志, 2021, 24(1): 10-13.

Rong Aimei,Zhang Chao,Wu Huili. Effect of sirolimus on peripheral blood Treg/Th17 cell ratio in high fat diet-induced NAFLD in rats[J]. Journal of Practical Hepatology, 2021, 24(1): 10-13.

参考文献

[1] Dongiovanni P , Meroni M , Baselli G A , et al. Insulin resistance promotes lysyl oxidase like 2 induction and fibrosis accumulation in nonalcoholic fatty liver disease. Clin Sci, 2017,131(12):1301-1315.
[2] Honda Y , Kessoku T , Ogawa Y , et al. The characteristics of non-obese non-alcoholic fatty liver disease: effect of genetic and environmental factors. J Hepatol, 2016,64(2):1011-1018.
[3] Younossi Z M , Koenig A B , Abdelatif D , et al. Global epidemiology of nonalcoholic fatty liver disease-Meta analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1):73-84.
[4] Deyo J C , Nicolsen N , Lachiewicz A , et al. Salvage treatment of mucormycosis post-liver transplant with posaconazole during sirolimus maintenance immunosuppression.J Pharm Pract, 2016, 30(2):261-265.
[5] 吴丽蒙.Treg和Th17细胞在慢加急性乙型肝炎肝衰竭发病机制中的作用研究进展.实用肝脏病杂志,2017,20(5):639-642.
[6] Dutkowski P , Polak W G , Muiesan P , et al. Firstcomparison of hypothermic oxygenated perfusion versus static cold storage of human donation after cardiac death liver transplants. Ann Surg, 2015, 262(5):764-770.
[7] Liu C , Wang Y . A 128-Channel, 710 Msamples/second, and less than 10 ps RMS resolution time-to-digital converter implemented in a kintex-7 FPGA. Nucl Sci, 2015, 62(3):773-783.
[8] Karia P S , Azzi J R , Heher E C , et al. Association of sirolimus use with risk for skin cancer in a mixed-organ cohort of solid-organ transplant recipients with a history of cancer. Jama Dermatol, 2016,152(5):533-540.
[9] Karayannopoulou G , Euvrard S , Kanitakis J . Differentialexpression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTORinhibitors in organ-transplant recipients. Anticancer Res, 2013, 33(9):3711-3714.
[10] Lin CW,Zhang H,Li M,et al. Pharmocological promotion of autophagy alleviates andinjury in alcoholic and non-alcoholic fatty liver conditions in mice.J Hepatol,2013,58(5):993-999.
[11] 吴旭玮,翁智远,王艳丽,等.血管紧张素转化酶2基因转染抑制非酒精性脂肪性肝病大鼠肝纤维化.中华肝脏病杂志, 2018, 26(10):771-774.
[12] 徐嘉妤, 敖娜, 都健,等.胰升糖素样肽1类似物对非酒精性脂肪肝大鼠IRE1α-JNK通路的干预效应.中华内分泌代谢杂志, 2015, 31(3):272-276.
[13] Zimmerman K O , Wu H , Greenberg R , et al. Therapeuticdrug monitoring, electronic health records, and pharmacokinetic modeling to evaluate sirolimus drug exposure-response relationships in renal transplant patients. Therap Drug Monit,2016, 38(5):1-7.
[14] Gheith O , Cerna M , Halim M A , et al. Sirolimus-induced combined posterior reversible encephalopathy syndrome and lymphocytic pneumonitis in a renal transplant recipient: case report and review of the literature. Exp Clin Transpl, 2017, 15(Suppl 1):170-174.
[15] Wong R J , Cheung R , Ahmed A . Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology, 2014, 59(6):2188-2195.
[16] 梁静, 韩涛, 景丽,等. 三种炎性因子在慢性乙型肝炎合并非酒精性脂肪性肝病患者血清中的表达及作用. 中华传染病杂志, 2017, 35(10):600-604.
[17] Jung K Y , Cho S Y , Kim H J , et al. Nonalcoholicsteatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology. J ClinGastroenterol, 2014, 48(10):883-888.
[18] Cai C , Zhu X , Li P , et al. NLRP3deletion inhibits the non-alcoholic steatohepatitis development and inflammation in Kupffer cells induced by palmitic acid. Inflammation, 2017, 40(6):1875-1883.
[19] 王天宝, 田玉伟, 朱斌. 急性肝损伤大鼠外周血辅助性T细胞17和调节性T细胞亚群及细胞因子的变化及意义. 中华实验外科杂志, 2019, 36(1):75-78.
[20] Seo W , Eun H S , Kim S Y , et al. Exosome‐mediated activation of toll‐like receptor 3 in stellate cells stimulates interleukin‐17 production by γδ T cells in liver fibrosis. Hepatology, 2016, 64(2):2271-2272.
[21] Musso G , Cassader M , Paschetta E , et al. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis. Jama Intern Med, 2017, 177(5):633-640.
[22] Min B H , Shin J S , Kim J M , et al. Delayed revascularization of islets aftertransplantation by IL-6 blockade in pig to non-human primate islet xenotransplantation model.Xenotransplantation, 2017, 25(1):124-127.
[23] Asrani S K , Wiesner R H , Trotter J F , et al. Denovo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant, 2014, 14(2):356-366.
[24] Schnitzbauer A A , Sothmann J , Baier L , et al. Calcineurin inhibitor free de novo immunosuppression in liver transplant recipients with pretransplant renal impairment: results of a pilot study (PATRON07). Transplantation, 2015, 99(12):2565-75.
[25] Sheng L , Jun S , Jianfeng L , et al. The effect of sirolimus‐based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation. Clin Transplant, 2015, 29(6):555-559.